Tumor cell markers and methods for detecting or harvesting tumor cells - Patents.com

By employing specific polypeptides as tumor markers, the method effectively detects and recovers epithelial marker-negative tumor cells, overcoming the limitations of existing markers and distinguishing them from contaminant cells, particularly leukocytes.

JP7593584B2Active Publication Date: 2024-12-03KYORIN UNIVERSITY +1
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2020040654
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-03-10
Publication Date
2024-12-03
Estimated Expiration
2040-03-10

AI Technical Summary

Technical Problem

Existing methods struggle to specifically and comprehensively detect epithelial marker-negative tumor cells, such as circulating tumor cells (CTCs), due to the limitations of current markers like vimentin and neural cadherin, which are not suitable for distinguishing them from contaminant cells, particularly leukocytes.

Method used

The use of specific polypeptides, including those with sequences from SEQ ID NOs: 1 to 92, as tumor markers, detected by antibodies or aptamers, to identify epithelial marker-negative tumor cells, allowing differentiation from contaminant cells.

Benefits of technology

Enables the detection and recovery of epithelial marker-negative tumor cells, even in the presence of contaminant cells, providing a more accurate method for identifying highly malignant tumor cells involved in metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593584000014
    Figure 0007593584000014
  • Figure 0007593584000001
    Figure 0007593584000001
  • Figure 0007593584000002
    Figure 0007593584000002
Patent Text Reader

Abstract

To provide a method for detecting or recovering an epithelial marker-negative tumor cell contained in a sample separately from a contaminating cell.SOLUTION: By detecting the expression of a specific polypeptide such as RAMP2 (GenBank No. NP_005845.2) in a sample, an epithelial marker-negative tumor cell contained in the sample can be detected or recovered separately from a contaminating cell.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a tumor cell marker and a method for detecting or recovering epithelial marker-negative tumor cells contained in a sample. In particular, the present invention may relate to a method for detecting or recovering epithelial marker-negative tumor cells contained in a sample, by distinguishing them from contaminating cells contained in the same sample. [Background technology]

[0002] When tumor cells leave the primary lesion, they penetrate into the blood vessels or lymphatic vessels, circulate in the blood or lymph, and finally invade other organs or tissues to form metastatic lesions. Here, tumor cells circulating in the blood are also called circulating tumor cells (CTCs), and many clinical trials and studies have been conducted on them. For example, by measuring the number of CTCs contained in the blood collected from a cancer patient (Patent Document 1), or by examining the expression of proteins or gene mutations or translocations in the CTCs, information regarding the prognosis prediction or cancer recurrence prediction of the patient can be provided.

[0003] For the detection of CTCs, cytokeratin and EpCAM (Epithelial In other words, CTCs are detected as epithelial marker-positive cells.

[0004] On the other hand, Non-Patent Document 1 reports that in tumor tissues dominated by epithelial cells, mesenchymal cells that have undergone epithelial to mesenchymal transition (EMT) and have low expression of epithelial markers are present, and that these mesenchymal cells are involved in cancer metastasis. In other words, it can be considered that epithelial marker-negative CTCs that have undergone epithelial-mesenchymal transition are more malignant and important than epithelial marker-positive CTCs. As an example, Patent Document 2 reports that epithelial marker-negative CTCs are useful for predicting the prognosis of cancer patients.

[0005] Here, it may be difficult to detect epithelial marker-negative CTCs specifically and comprehensively using only epithelial markers as indicators. As a method for detecting epithelial marker-negative CTCs, for example, a method using mesenchymal markers such as vimentin and N-cadherin (Patent Documents 3 and 4) and TROP2 (Patent Document 5) has been reported. However, since vimentin is also highly expressed in white blood cells in the blood, it is not suitable for specific detection of epithelial marker-negative CTCs. In addition, since N-cadherin and TROP2 are expressed only in a portion of CTCs that have undergone epithelial-mesenchymal transition, they are insufficient for comprehensive detection of epithelial marker-negative CTCs. Therefore, a marker that is more useful for specific and comprehensive detection of epithelial marker-negative CTCs is required. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 2008-533487 [Patent Document 2] JP 2017-129584 A [Patent Document 3] Special Publication No. 2014-533828 [Patent Document 4] Special Publication No. 2016-512197 [Patent Document 5] Special Publication No. 2018-517888 [Non-patent literature]

[0007] [Non-Patent Document 1] Simon, A. Joosse.et al., CANCER RESEARCH,73,8-11(2013) Summary of the Invention [Problem to be solved by the invention]

[0008] An object of the present invention is to provide a method for detecting or recovering epithelial marker-negative tumor cells contained in a sample. In one aspect, an object of the present invention is to provide a method for detecting or recovering epithelial marker-negative tumor cells contained in a sample while distinguishing them from contaminating cells contained in the sample. [Means for solving the problem]

[0009] As a result of intensive research to solve the above-mentioned problems, the inventors discovered a marker that can be used to detect or recover epithelial marker-negative tumor cells contained in a sample, and distinguish them from contaminating cells contained in the sample, thereby completing the present invention.

[0010] That is, the present invention can be exemplified as follows. [1] 1. A method for detecting a target cell in a sample, comprising: detecting a tumor marker in the sample, the target cell is a tumor cell negative for at least one epithelial marker; The method, wherein the tumor marker is one or more polypeptides selected from the group consisting of the following (1) to (4): (1) a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92; (2) A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92, which contains a deletion, substitution, insertion, and / or addition of one to several amino acid residues; (3) a polypeptide comprising an amino acid sequence having 70% or more homology to the entire amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92; (4) A polypeptide which is a splicing variant of the polypeptides (1) to (3). [2] The method, wherein the tumor marker is detected using an antibody or an aptamer that specifically recognizes the tumor marker. [3] The method, wherein the tumor marker is detected by detecting a transcription product of a gene encoding the tumor marker. [4] The method, wherein the sample contains contaminating cells. [5] The method, wherein the contaminating cells are white blood cells. [6] The method, wherein the sample is a sample obtained from a subject. [7] The method, wherein the subject is a cancer subject. [8] The method, wherein the subject is a human. [9] The method, wherein the sample is a blood-derived sample.

[10] The above method, wherein the epithelial marker is cytokeratin and / or EpCAM (epithelial cell adhesion molecule).

[11] The method, wherein the tumor marker is one or more polypeptides selected from the group consisting of the following (5) to (8): (5) A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 23; (6) A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 23, which contains a deletion, substitution, insertion, and / or addition of one to several amino acid residues; (7) A polypeptide comprising an amino acid sequence having 70% or more homology to the entire amino acid sequence set forth in any one of SEQ ID NOs: 1 to 23; (8) A polypeptide which is a splicing variant of any of the polypeptides (5) to (7).

[12] the sample is obtained from a subject, the subject is a cancer subject, The detection determines the number of the target cells in the sample. The method.

[13] 1. A method for recovering target cells in a sample, comprising: detecting said target cells in said sample by said method; and Recovering the detected target cells. A method comprising:

[14] A method for predicting the prognosis of a subject, comprising: determining the number of target cells in the sample by the method; and Correlating said number with a prognosis for said subject. A method comprising: Effect of the Invention

[0011] According to the present invention, epithelial marker-negative tumor cells contained in a sample can be recovered or detected. According to one aspect, according to the present invention, epithelial marker-negative tumor cells contained in a sample can be recovered or detected while being distinguished from contaminating cells contained in the sample. [Brief description of the drawings]

[0012] [Figure 1]1 shows the results of RAMP2 gene expression analysis of white blood cells and epithelial marker-negative CTCs, in which WBC1 to WBC4 represent the results of expression analysis of white blood cells, and CTC1 to CTC10 represent the results of expression analysis of epithelial marker-negative CTCs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The present invention will be described in detail below.

[0014] <1> Detection Method The detection method of the present invention is a method for detecting target cells in a sample. Specifically, the detection method of the present invention may be a method for detecting target cells in a sample while distinguishing them from contaminating cells in the sample.

[0015] The target cells can be detected by using a specific polypeptide as a tumor marker. Hereinafter, the specific polypeptide is also referred to as a "tumor marker." That is, the detection method of the present invention may include a step of detecting the expression of a tumor marker in a sample. This step is also referred to as a "detection step." Specifically, the detection step is a step of detecting the expression of a tumor marker in a sample. The detection step may be a step of detecting a target cell by detecting the expression of a tumor marker in a sample. The target cell can be detected as a tumor marker-positive cell. That is, more specifically, the detection step may be a step of detecting a tumor marker-positive cell as a target cell by detecting the expression of a tumor marker in a sample.

[0016] The sample is not particularly limited as long as it can contain target cells. The sample may be, for example, a sample obtained from a subject. Examples of the sample include blood samples such as blood (whole blood), diluted blood, serum, plasma, cerebrospinal fluid, umbilical cord blood, and blood component collection; samples that can contain blood components such as urine, saliva, semen, feces, phlegm, amniotic fluid, and ascites; suspensions of tissue fragments (tissue suspensions) such as liver, lung, spleen, kidney, skin, tumor, and lymph node; and fractions thereof. For example, the tissue suspension can be obtained by suspending tissue fragments in a liquid medium. Examples of the liquid medium include water and aqueous buffer solutions. Examples of the fractions include fractions containing cells derived from the above-mentioned samples. Specific examples of the fractions include fractions containing cells obtained by subjecting the above-mentioned samples to centrifugation such as density gradient centrifugation. Examples of the sample include, in particular, blood samples, samples that can contain blood components, and fractions thereof (hereinafter, collectively referred to as "blood-derived samples"). A blood-derived sample can be relatively easy to collect from a subject. The sample may be used in the detection step, for example, as is, or after being subjected to an appropriate operation such as dilution or concentration. The sample may be used in the detection step, for example, in the form of a suspension.

[0017] For example, additives may be added to the sample. Additives may be added particularly to blood-derived samples. Examples of additives include anticoagulants, antiplatelet agents, formaldehyde donor compounds (compounds capable of releasing formaldehyde through hydrolysis), and polyethylene glycol. Examples of anticoagulants include chelating agents such as citric acid and ethylenediaminetetraacetic acid (EDTA). These additives may contribute, for example, to stabilizing target cells. As the additive, one type of additive may be used, or two or more types of additives may be used in combination. The additives may be added, for example, at the time of collection of the sample from the subject, or after collection of the sample from the subject. When two or more types of additives are used, the additives may or may not be added to the sample at the same time. For example, a solution containing two or more types of additives may be added to the sample, or solutions containing each of the additives may be added to the sample individually. A blood-derived sample to which a formaldehyde donor compound, an antiplatelet agent, and an anticoagulant have been added (a preserved blood-derived sample) may be stably stored for at least 7 days at low temperatures to room temperature (e.g., 0°C to 30°C) where the sample does not freeze.

[0018] The sample may be used in the detection step after being subjected to, for example, cell fixation or membrane permeabilization. Examples of fixation agents include formaldehyde, formaldehyde donor compounds, aldehydes such as glutaraldehyde, alcohols such as methanol and ethanol, and solutions containing heavy metals. Examples of membrane permeabilization agents include alcohols such as methanol and ethanol, and surfactants such as saponin.

[0019] The subject is not particularly limited. The subject may be, for example, a cancer subject. "Cancer subject" means a subject that has had or is suffering from cancer. The subject may be a subject before cancer treatment, a subject during cancer treatment, or a subject after cancer treatment. The subject may be, in particular, a subject after cancer treatment. The subject may be a human or a non-human animal. Non-human animals include mice, rats, guinea pigs, rabbits, dogs, cats, cows, horses, pigs, monkeys, chimpanzees, and birds. The subject may be, in particular, a human.

[0020] The type of cancer is not particularly limited. The cancer may be a primary cancer or a metastatic cancer. Examples of cancer include hematopoietic cell malignant tumors, head and neck cancer, brain tumors, breast cancer, uterine body cancer, cervical cancer, ovarian cancer, and esophageal cancer. Examples of cancer include esophageal cancer, stomach cancer, appendix cancer, colon cancer, liver cancer, gallbladder cancer, bile duct cancer, pancreatic cancer, kidney cancer, adrenal cancer, gastrointestinal stromal tumor, mesothelioma, thyroid cancer, lung cancer, osteosarcoma, bone cancer, prostate cancer, testicular tumor, bladder cancer, skin cancer, and anal cancer. Examples of hematopoietic cell malignant tumors include leukemia, lymphoma, and multiple myeloma. Examples of lymphomas include Hodgkin's lymphoma and non-Hodgkin's lymphoma. Examples of head and neck cancers include floor of the mouth cancer, gingival cancer, tongue cancer, buccal mucosa cancer, salivary gland cancer, and paranasal sinus cancer. Examples of cancers include prostate cancer in particular.

[0021] The sample may contain contaminating cells. "Contaminating cells" refers to cells other than target cells. Contaminating cells include red blood cells, white blood cells, and platelets. Contaminating cells include, in particular, white blood cells. Contaminating cells such as red blood cells, white blood cells, and platelets may be contained in, for example, a blood-derived sample. The detection method of the present invention may be particularly effective in distinguishing between target cells and white blood cells in a blood-derived sample such as a blood sample.

[0022] The target cells are epithelial marker-negative tumor cells. The target cells can be detected as tumor marker-positive cells. That is, tumor marker-positive cells may be regarded as epithelial marker-negative tumor cells. In other words, the target cells are tumor marker-positive and epithelial marker-negative tumor cells. The fact that the target cells are epithelial marker-negative can be confirmed, for example, by measuring the expression of the epithelial marker in the target cells. Examples of tumor cells include circulating tumor cells (CTCs). CTCs can be contained in blood-derived samples in particular. Tumor cells in blood-derived samples may typically be regarded as CTCs. The fact that the target cells are epithelial marker-negative suggests that they are highly malignant tumor cells. Examples of highly malignant tumor cells include tumor cells that have undergone epithelial-mesenchymal transition and tumor cells that are involved in bone metastasis. Examples of tumor cells that have undergone epithelial-mesenchymal transition include tumor cells that are positive for mesenchymal markers such as vimentin and N-cadherin. The target cells may be present, for example, as single cells or may form cell clusters. A cell cluster may contain one or more target cells. A cell cluster may or may not contain cells other than the target cells in addition to the target cells.

[0023] Epithelial markers include EpCAM (epithelial cell adhesion molecule) and cytokeratin (CK). CK includes CK1 to CK20 (i.e., CK1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20). CK includes, in particular, cytokeratin 8 (CK8; also called KRT8). As the epithelial marker, one epithelial marker may be used, or a combination of two or more epithelial markers may be used. "Epithelial marker negative" may mean that at least one epithelial marker is negative. When a combination of two or more epithelial markers is used, it is sufficient that at least one epithelial marker is negative in the target cells. When a combination of two or more epithelial markers is used, two or more epithelial markers may be negative in the target cells.

[0024] The detection of target cells may be, for example, qualitative detection (for example, detection of the presence or absence of target cells in a sample) or quantitative detection (for example, detection of the amount of target cells present in a sample). The amount of target cells present may be the number of target cells. That is, in the detection step, for example, the number of target cells may be measured. That is, the detection step may be, for example, a step of detecting the expression of a tumor marker in a sample and measuring the number of target cells. The number of target cells in a sample can be measured by detecting the target cells in the sample and counting the number. The number of target cells may be calculated, for example, as the number of target cells per unit amount (for example, unit weight or unit volume) of sample.

[0025] The method for detecting the expression of a marker such as a tumor marker or an epithelial marker is not particularly limited. "Detection" and "measurement" may be used interchangeably. "Expression of a marker" and "expression of a gene encoding a marker" may be used interchangeably. A gene encoding a marker is also called a "marker gene". The detection of the expression of a detection marker may be, for example, a qualitative detection (e.g., detection of the presence or absence of expression of a marker) or a quantitative detection (e.g., detection of the degree of expression of a marker). The detection of the expression of a marker can be carried out, for example, by detecting an expression product of a marker gene. Examples of the expression product of a marker gene include a transcription product of the marker gene (i.e., an mRNA encoding a marker) and a translation product of the marker gene (i.e., a marker). Examples of the expression product of a marker gene include, in particular, a marker. The detection of the expression product of a marker gene may be, for example, a qualitative detection (e.g., detection of the presence or absence of an expression product) or a quantitative detection (e.g., detection of the amount of an expression product).

[0026] The expression of the marker may be detected directly, usually by measuring the expression product of the marker gene held by the cell. In addition, when the expression product of the marker gene is present outside the cell due to secretion of the expression product of the marker gene, the expression of the marker may be detected indirectly, usually by measuring the expression product of the marker gene present outside the cell. That is, the target cell may be detected directly, usually by measuring the expression product of the tumor marker gene held by the target cell. In addition, when the expression product of the tumor marker gene is present outside the target cell due to secretion of the expression product of the tumor marker gene, the target cell may be detected indirectly, usually by measuring the expression product of the tumor marker gene present outside the target cell.

[0027] The method for measuring the expression product of the marker gene is not particularly limited. The expression product of the marker gene can be measured by an appropriate method depending on the type of the expression product. The expression product of the marker gene can be measured, for example, by a known method for quantifying mRNA or protein.

[0028] The marker can be detected, for example, by using an antibody against the marker, an aptamer against the marker, or a dye capable of specifically staining the marker (for example, a chemiluminescent dye or a fluorescent dye). The marker may be detected, in particular, by using an antibody against the marker or an aptamer. The marker may be detected, more particularly, by using an antibody against the marker. By using an antibody against the marker, for example, the marker can be detected simply, sensitively, and specifically. The antibody or the aptamer may be modified with a labeling substance as appropriate. Examples of the labeling substance include fluorescent substances such as fluorescein isothiocyanate (FITC), phycoerythrin (PE), and Alexa Fluor (trade name), enzymes such as alkaline phosphatase and horseradish peroxidase, and radioactive substances. The binding mode between the antibody or the aptamer and the labeling substance is not particularly limited. The antibody or the aptamer may be directly bound to the labeling substance, or may not be directly bound to the labeling substance. For example, the antibody may be directly bound to the labeling substance by chemical bonding or the like, or may be indirectly bound to the labeling substance by binding to a secondary antibody (labeled secondary antibody) bound to the labeling substance. Specifically, the marker can be detected by, for example, an EIA (Enzyme Immunoassay) method or a Western blot method using an antibody against the marker. Examples of the EIA method include the Enzyme-Linked ImmunoSorbent Assay (ELISA), the Chemiluminescent Enzyme Immunoassay (CLEIA), and the Fluorescence Enzyme Immunoassay (FEIA). Immunoassay method. Markers may be detected manually or automatically using a measuring device. Examples of measuring devices include enzyme immunoassay devices such as AIA-900 (Tosoh) and chemiluminescence enzyme immunoassay devices such as AIA-CL2400 (Tosoh).

[0029] The mRNA encoding the marker can be detected, for example, by a hybridization method using a probe that specifically hybridizes to the mRNA. The mRNA encoding the marker can also be amplified and detected by a PCR method, an RT-PCR method, a TRC (Transcription Reverse Transcription Concerted) method, a NASBA (Nucleic Acid Sequence-Based Amplification) method, or a TMA (Transcription-Mediated Amplification) method using a primer set that can specifically amplify the mRNA. The mRNA encoding the marker can also be detected by directly subjecting the sample to base sequence analysis.

[0030] Detection and counting of the labeled target cells may be carried out, for example, using a microscope, an optical detector, or a flow cytometer. Microscopes include fluorescent microscopes.

[0031] The labeled target cells may be detected and counted, for example, based on a stained image (e.g., a fluorescent image). The detection and counting of the target cells based on a stained image (e.g., a fluorescent image) may be performed, for example, manually, or automatically using software that automatically reads the target cells. In addition to the stained image (e.g., a fluorescent image), the detection and counting of the labeled target cells may be performed with reference to the observation results of a bright field image.

[0032] When detecting the expression of multiple markers, the expression of those markers may be detected, for example, individually or collectively at the same time.

[0033] Detection of expression of a marker may be performed, for example, on a sample containing a plurality of cells, or on a single cell isolated from the sample. Detection of expression of a marker may be performed particularly on a sample containing a plurality of cells.

[0034] The criteria for determining whether a marker is negative / positive are not particularly limited as long as the target cells can be detected to a desired extent. The criteria for determining whether a marker is negative / positive can be appropriately set depending on various conditions, such as the purpose of detecting the target cells.

[0035] For example, when no expression of the marker is observed (for example, when no detection signal of the marker is observed), the marker may be determined to be negative. For example, when the expression level of the marker is below a predetermined threshold (for example, when the intensity of the detection signal of the marker is below a predetermined threshold), the marker may be determined to be negative. For example, when the expression level of the marker is equal to or lower than the expression level of the marker in the negative control cells (for example, when the intensity of the detection signal of the marker is equal to or lower than the detection signal of the marker in the negative control cells), the marker may be determined to be negative. For example, when the expression level of the marker is less than half, less than 1 / 3, less than 1 / 5, or less than 1 / 10 of the expression level of the marker in the positive control cells (for example, when the intensity of the detection signal of the marker is less than half, less than 1 / 3, less than 1 / 5, or less than 1 / 10 of the detection signal of the marker in the positive control cells), the marker may be determined to be negative.

[0036] For example, a marker may be determined to be positive when even the slightest expression of the marker is observed (e.g., when even the slightest detection signal of the marker is observed). Alternatively, a marker may be determined to be positive when, for example, the expression level of the marker is equal to or higher than a predetermined threshold (e.g., when the intensity of the detection signal of the marker is equal to or higher than a predetermined threshold). Alternatively, a marker may be determined to be positive when, for example, the expression level of the marker is equal to or higher than the expression level of the marker in a positive control cell (e.g., when the intensity of the detection signal of the marker is equal to or higher than the detection signal of the marker in a positive control cell). The marker may be determined to be positive when the expression level of the marker is significantly higher than that of the marker in the negative control cells (for example, when the intensity of the detection signal of the marker is higher than that of the detection signal of the marker in the negative control cells by a certain value or more, or when the intensity of the detection signal of the marker is the mean value +2SD or more, the mean value +3SD or more, or the mean value +4SD or more of the detection signal of the marker in the negative control cells).

[0037] "Negative control cells" refer to cells that are negative for the marker. "Positive control cells" refer to cells that are positive for the marker. Negative control cells for tumor markers include contaminating cells such as red blood cells and white blood cells. Negative control cells for epithelial markers include vascular endothelial cells and mesenchymal stem cells. Positive control cells for epithelial markers include epithelial cells.

[0038] According to the detection method of the present invention, target cells can be specifically detected. That is, according to the detection method of the present invention, even if the sample contains contaminating cells, target cells can be detected by distinguishing them from the contaminating cells. According to the detection method of the present invention, target cells present only in small amounts in a sample containing contaminating cells may be detected. "Detecting target cells in a sample by distinguishing them from contaminating cells" may mean, for example, identifying the presence or absence or the amount of target cells in a sample containing contaminating cells, and may mean, in particular, identifying whether each cell in the sample is a target cell or a contaminating cell. For example, at least when detecting and recovering target cells by distinguishing them from contaminating cells, each recovered cell may be identified as a target cell. Specifically, by detecting the expression of a tumor marker in each cell, it is possible to identify whether each cell is a target cell or a contaminating cell. That is, cells expressing a tumor marker can be considered as target cells rather than contaminating cells, that is, they can be detected by distinguishing them from contaminating cells. The expression of a tumor marker in each cell can be detected, for example, by detecting the expression product of a tumor marker gene retained in each cell.

[0039] Specific polypeptides include polypeptides comprising the amino acid sequences set forth in SEQ ID NOs: 1 to 92 and variants thereof. Specific polypeptides particularly include polypeptides comprising the amino acid sequences set forth in SEQ ID NOs: 1 to 23 and variants thereof. Each variant of a polypeptide comprising the amino acid sequence set forth in SEQ ID NOs: 1 to 92 may have the same function as, for example, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NOs: 1 to 92. As the specific polypeptide, one type of polypeptide may be used, or two or more types of polypeptides may be used in combination.

[0040] Specific polypeptides (i.e., tumor markers) include the following polypeptides (1) to (4): (1) a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92; (2) A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92, which contains a deletion, substitution, insertion, and / or addition of one to several amino acid residues; (3) a polypeptide comprising an amino acid sequence having 70% or more homology to the entire amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92; (4) A polypeptide which is a splicing variant of any of the polypeptides (1) to (3).

[0041] Specific polypeptides (i.e., tumor markers) include, in particular, the following polypeptides (5) to (8): (5) A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 23; (6) In the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 23, one to several amino acids a polypeptide comprising an amino acid sequence that includes deletions, substitutions, insertions, and / or additions of amino acid residues; (7) A polypeptide comprising an amino acid sequence having 70% or more homology to the entire amino acid sequence set forth in any one of SEQ ID NOs: 1 to 23; (8) A polypeptide which is a splicing variant of any of the polypeptides (5) to (7).

[0042] The polypeptides (1) to (8) may be any of the polypeptides expressed by target cells. The polypeptides (5) to (8) may be transmembrane polypeptides among the polypeptides (1) to (4). The polypeptides (5) to (8) may be used as tumor markers, particularly when recovering target cells.

[0043] A particular polypeptide may be, for example, a polypeptide comprising the amino acid sequence set forth in any of SEQ ID NOs: 1 to 92 (eg, SEQ ID NOs: 1 to 23).

[0044] Furthermore, a specific polypeptide may be, for example, a polypeptide having an amino acid sequence including deletion, substitution, insertion, and / or addition of one to several amino acid residues in the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92 (e.g., SEQ ID NOs: 1 to 23). "Several" may mean, for example, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2. "One to several" may mean, for example, preferably 1 to 10 amino acid residues, more preferably 1 to 5, even more preferably 1 to 3, and particularly preferably 2 or less.

[0045] Furthermore, the specific polypeptide may be, for example, a polypeptide having high homology to the entire amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92 (for example, SEQ ID NOs: 1 to 23). "High homology" may mean, for example, 70% or more, preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more homology. "Homology" may mean identity or similarity. "Identity" between amino acid sequences means the ratio of amino acid residues of the same type in those amino acid sequences (Experimental Medicine, February 2013, Vol. 31, No. 3, Yodosha). "Similarity" between amino acid sequences means the sum of the ratio of amino acid residues of the same type in those amino acid sequences and the ratio of amino acid residues with similar side chain properties (Experimental Medicine, February 2013, Vol. 31, No. 3, Yodosha). The homology of amino acid sequences can be determined, for example, by using alignment programs such as BLAST and FASTA.

[0046] Furthermore, in eukaryotic cells, when expressing a protein from a gene, a reaction (splicing) may occur in which an intron in a pre-mRNA is removed and the preceding and following exons are recombined. Since there is diversity in the combination of exons remaining after splicing and various mature mRNAs may be produced, proteins with different amino acid sequences (splice variants) may be expressed. Thus, a particular polypeptide may be, for example, a splice variant of the polypeptide exemplified above. Note that, depending on the context, the term "splice variant" may refer to a polypeptide expressed as a splice variant, or may refer to the amino acid sequence thereof.

[0047] Splicing variants of the above-exemplified polypeptides include the following: A polypeptide comprising a splicing variant of the amino acid sequence set forth in any of SEQ ID NOs: 1 to 92 (e.g., SEQ ID NOs: 1 to 23); An amino acid sequence set forth in any one of SEQ ID NOs: 1 to 92 (e.g., SEQ ID NOs: 1 to 23). a polypeptide comprising an amino acid sequence containing one or more deletions, substitutions, insertions, and / or additions of amino acid residues in a splicing variant of the above; A polypeptide comprising an amino acid sequence having 70% or more homology to the entire splicing variant of any of the amino acid sequences set forth in SEQ ID NOs: 1 to 92 (e.g., SEQ ID NOs: 1 to 23).

[0048] The gene (tumor marker gene) encoding a specific polypeptide is not particularly limited as long as it is a polynucleotide containing a base sequence obtained by converting the specific polypeptide as exemplified above according to codons. The gene encoding a specific polypeptide may be, in particular, a polynucleotide containing a base sequence obtained by converting the specific polypeptide as exemplified above according to human codons. Specific examples of genes encoding specific polypeptides include polynucleotides having the base sequences set forth in SEQ ID NOs: 93 to 184.

[0049] Examples of specific polypeptides and genes encoding them are shown in Tables 1 to 4. In addition, the formal names (full names) and aliases of each protein listed in Tables 1 to 4 are shown in Tables 5 to 13.

[0050] [Table 1]

[0051] [Table 2]

[0052] [Table 3]

[0053] [Table 4]

[0054] [Table 5]

[0055] [Table 6]

[0056] [Table 7]

[0057] [Table 8]

[0058] [Table 9]

[0059] [Table 10]

[0060] [Table 11]

[0061] [Table 12]

[0062] [Table 13]

[0063] <2> Collection method The recovery method of the present invention is a method for recovering target cells in a sample. Specifically, the recovery method of the present invention may be a method for recovering target cells in a sample by distinguishing them from contaminating cells in the sample.

[0064] The target cells may be detected by the detection method of the present invention and then recovered. That is, the recovery method of the present invention may include a step of detecting target cells in a sample by the detection method of the present invention, and a step of recovering the detected target cells. The latter step is also called a "recovery step". For the detection and recovery of the target cells, one or more polypeptides selected from the group consisting of (1) to (4) may be used as a tumor marker, and in particular, one or more polypeptides selected from the group consisting of (5) to (8) may be used as a tumor marker.

[0065] According to the recovery method of the present invention, target cells can be recovered specifically. That is, according to the recovery method of the present invention, even if a sample contains contaminating cells, the target cells can be recovered in distinction from the contaminating cells. That is, by recovering the target cells detected in distinction from the contaminating cells, the target cells can be recovered in distinction from the contaminating cells. According to the recovery method of the present invention, in particular, target cells present only in small amounts in a sample containing contaminating cells may be recovered.

[0066] The method for recovering target cells in a sample is not particularly limited. Target cells in a sample can be recovered, for example, using a recovery device. Examples of the recovery device include a device equipped with a substrate provided with a holding part capable of holding target cells and a recovery part that recovers target cells by suction and discharge using a nozzle. Specific examples of such devices include the recovery device described in JP 2016-142616 A.

[0067] <3> Forecasting Methodology When the sample is obtained from a subject and the subject has cancer, the prognosis of the subject can be predicted based on the result of the detection step. That is, the prediction method of the present invention is a method for predicting the prognosis of a subject.

[0068] The prognosis of a subject can be predicted, for example, based on the number of target cells in a sample obtained from the subject. The prognosis of a subject can be predicted, for example, by correlating the number of target cells in a sample obtained from the subject with the prognosis of the subject. That is, the prediction method of the present invention may include a step of measuring the number of target cells in a sample obtained from the subject, and a step of correlating the number with the prognosis of the subject. The former step is also called a "measurement step", and the latter step is also called an "association step". The measurement step is an example of a detection step. That is, the measurement step can be performed by carrying out the detection method of the present invention, specifically by carrying out the detection step. The association step may be, specifically, a step of predicting the prognosis of a subject by correlating the number of target cells in a sample obtained from the subject with the prognosis of the subject.

[0069] The association can be performed based on data showing the correlation between the number of target cells in a sample obtained from a subject and the prognosis of the subject (hereinafter, also referred to as "correlation data"). The correlation data can be created, for example, by measuring the number of target cells in a sample obtained from a cancer population, tracking the prognosis of the cancer population, and analyzing the correlation between the number of target cells and the prognosis. The description of the subject can be applied mutatis mutandis to the individual for creating the correlation data. For example, a "cancer individual" means an individual who has had or is suffering from cancer. The number of individuals for creating the correlation data is not particularly limited, and may be, for example, 2 or more individuals, 5 or more individuals, 10 or more individuals, 20 or more individuals, 50 or more individuals, or 100 or more individuals. The correlation data may be used for the association in an easy-to-handle form, such as an identification table or graph.

[0070] For example, the lower the number of target cells in a sample obtained from a subject, the better the prognosis may be predicted. Also, for example, when the number of target cells in a sample obtained from a subject is low compared to a predetermined threshold, the better the prognosis may be predicted. When a decrease in the number of target cells is observed, a good prognosis may be predicted. Also, for example, a greater decrease in the number of target cells in a sample or a smaller increase in the number of target cells in a sample in a subject may be predicted to have a good prognosis.

[0071] Also, for example, the greater the number of target cells in a sample obtained from a subject, the worse the prognosis may be predicted. Also, for example, when the number of target cells in a sample obtained from a subject is greater than a predetermined threshold, the worse the prognosis may be predicted. Also, for example, when an increase in the number of target cells in a sample is observed in a subject, the worse the prognosis may be predicted. Also, for example, when the degree of decrease in the number of target cells in a sample in a subject is smaller, or the degree of increase in the number of target cells in a sample is larger, the worse the prognosis may be predicted.

[0072] The prediction of prognosis may be, for example, a qualitative prediction (e.g., a prediction of whether the prognosis will be good or poor) or a quantitative prediction (e.g., a prediction of the degree of possibility that the prognosis will be good or poor, or a prediction of the degree of goodness or poorness when the prognosis is good or poor). For example, predicting a good prognosis includes predicting that the prognosis will be good, predicting that there is a high possibility that the prognosis will be good, and predicting that the degree of goodness will be high when the prognosis is good. For example, predicting a bad prognosis includes predicting that the prognosis will be poor, predicting that there is a high possibility that the prognosis will be poor, and predicting that the degree of poorness will be high when the prognosis is poor.

[0073] The prognosis is not particularly limited as long as it is related to cancer. Examples of prognosis include survival time, survival rate, the presence or absence or possibility of cancer worsening, the presence or absence or possibility of cancer improvement, the presence or absence or possibility of cancer recurrence, and the presence or absence or possibility of cancer metastasis. When predicting the prognosis, other parameters may be considered in addition to the number of target cells. Examples of other parameters include treatment status such as curative group / recurrent group / treatment-required group, progression such as stage I / II / III / IV, survival rate such as 1-year / 3-year / 5-year / 10-year survival rate, and malignancy such as Gleason score. That is, specific examples of prognosis include prognosis based on treatment status such as curative group / recurrent group / treatment-required group, prognosis based on progression such as stage I / II / III / IV, prognosis based on survival rate such as 1-year / 3-year / 5-year / 10-year survival rate, and prognosis based on malignancy such as Gleason score. The Gleason score is used, for example, to determine the malignancy of prostate cancer. It is expected that the prognosis can be accurately predicted by evaluating the number of target cells in combination with parameters such as treatment state, progression, survival rate, and malignancy. The prognosis may be, in particular, a treatment prognosis. That is, for example, the treatment prognosis can be predicted by carrying out the prediction method of the present invention on a subject after cancer treatment.

[0074] The association step may be performed, for example, by a doctor or by a person other than a doctor. The association step may be performed, for example, by a medical professional other than a doctor, such as a medical assistant. The association step may also be performed automatically by a computer (specifically, for example, a measuring device or a program). The prediction result by the prediction method of the present invention can be used, for example, by a medical professional such as a doctor to diagnose the prognosis of a subject. Therefore, the prediction method of the present invention may be considered as a preliminary method for diagnosing the prognosis of a subject.

[0075] The prediction method of the present invention can provide accurate information for determining a treatment plan and monitoring the effectiveness of treatment. The prediction method of the present invention provides a doctor with information regarding the risk of a disease condition that a subject has and the probability of survival, allowing the doctor to select the most appropriate treatment method, which leads to a reduction in the risk of subjecting a subject to unnecessary treatment. Therefore, the prediction method of the present invention can not only save costs for unnecessary treatment, but also contribute to improving the prognosis of a subject by selecting the most appropriate treatment. For example, a subject predicted by the prediction method of the present invention to be in the treatment-requiring group or to have a low survival rate may be further subjected to appropriate medical procedures such as administration of an anticancer drug, radiation therapy, or surgery. Furthermore, the prediction method of the present invention can be used not only to diagnose the prognosis of a subject, but also to, for example, to determine the prognosis of a subject. This technology can also be applied to the early detection of tumors and diagnosis of metastasis in healthy individuals.

[0076] <4> Program of the present invention The present invention provides a program for causing a computer to execute the steps included in the method of the present invention. The program is also referred to as the "program of the present invention." The "method of the present invention" may collectively refer to the detection method of the present invention, the recovery method of the present invention, and the prediction method of the present invention.

[0077] That is, in the present invention, the steps included in the method of the present invention may be executed by a computer. The computer may execute some or all of the steps included in the method of the present invention. The computer may execute, for example, the detection step and / or the prediction step.

[0078] Specifically, for example, a medical professional can obtain a sample such as a blood-derived sample from a subject, pre-treat it as necessary, and set it in a measuring device. The computer can cause the measuring device to measure the expression of a marker such as a tumor marker in the sample to detect target cells. The computer can further predict the prognosis of the subject based on the detection result of the target cells. The computer can further output the prediction result thus obtained, so that a medical professional can obtain the prediction result and use it to diagnose the prognosis of the subject.

[0079] The program of the present invention may be recorded in a computer-readable recording medium and provided. The term "computer-readable recording medium" refers to a recording medium in which information such as data and programs is stored by electrical, magnetic, optical, mechanical, or chemical action, and the stored information can be read by a computer. Examples of such recording media include floppy (registered trademark) disks, magneto-optical disks, CD-ROMs, CD-R / Ws, DVD-ROMs, DVD-R / Ws, DVD-RAMs, DATs, 8mm tapes, memory cards, hard disks, ROMs (read-only memories), and SSDs. In addition, the program of the present invention may be recorded such that each step executed by a computer is recorded as a separate program. EXAMPLES

[0080] Hereinafter, the present invention will be described in more detail using an example in which the sample is a blood sample and the target cells are epithelial marker-negative CTCs (circulating tumor cells), but the present invention is not limited to this example.

[0081] Example 1 Gene expression analysis of epithelial marker-negative CTCs Gene expression analysis of epithelial marker-negative CTCs and leukocytes contained in blood samples from prostate cancer patients was performed using the following method.

[0082] (1) Blood samples (whole blood) were collected from prostate cancer patients, and 10 times the amount of collected blood was added to 1x BD Pharm Lyse (Becton Dickinson). The blood was then incubated at room temperature for 10 minutes, and then lysed in D-PBS(-) (Dulbecco's Phosphate-Buffered Saline, Mg) containing 0.5% (w / v) BSA (bovine serum albumin) and 2 mM EDTA. 2+ and Ca 2+ The cells contained in the blood sample were washed with a buffer containing no erythrocytes (hereinafter simply referred to as "buffer") and suspended in the buffer.

[0083] (2) 50 μL of FcR Blocking Reagent (Miltenyi Biotec) was added to 50 μL of the cell suspension (1) and mixed. Then, 50 μL of PE (phycoerythrin)-labeled anti-TM4SF1 (Transmembrane 4 L6 family member 1) antibody solution (PE-anti-human TM4SF1 An tibody, R&D systems), PE-labeled anti-TNFRSF12A (Tumor 2.5μL of necrosis factor receptor superfamily member 12A (PE-anti-human TNFRSF12A Antibody, Biolegend), 10μL of PE-labeled anti-EpCAM (Epithelial cell adhesion molecule) (PE-anti-human EpCAM Antibody, Miltenyi Biotec), 10μL of FITC (fluorescein isothiocyanate)-labeled anti-CD45 (CD45-BB515, BD), and 1mg / mL Hoechst 33342 solution 1.1μL (Dojindo Laboratories) were added and mixed. After incubation for 10 minutes in a refrigerator, the cells were washed with buffer and suspended in buffer.

[0084] (3) To 80 μL of the cell suspension from (2), 20 μL of Anti-PE Microbeads UltraPure (Miltenyi Biotec) was added and incubated in a refrigerator for 15 minutes. The cells were then washed with buffer and suspended in buffer.

[0085] (4) An MS column (Miltenyi Biotec) was placed in a MACS Separator (Miltenyi Biotec) and washed with buffer. After that, 500 μL of the cell suspension from (3) was added, and the column was washed three times with 500 μL of buffer.

[0086] (5) After washing, the column was removed from the MACS Separator, 1 mL of buffer was added to the column, and the cells were recovered by pushing the plunger into the column.

[0087] (6) The collected cells were seeded on a slide glass, and among the Hoechst 33342-positive cells, FITC-positive (CD45 antibody-positive) and PE-positive (positive for one or more of the cancer marker antibodies TM4SF1, TNFRSF12A, and EpCAM) cells were detected under a fluorescent microscope as CTCs. The detected CTCs were collected using a MicroPick System (Nepa Gene).

[0088] (7) The collected CTCs (31 samples in total) and leukocytes obtained from healthy blood (4 samples in total) were analyzed using SMART-Seq v4 Ultra Low Input RNA cDNA synthesis and amplification were performed using the Kit for Sequencing (Clontech).

[0089] (8) Using 1 ng of the cDNA obtained in (7), libraries were prepared using the Nextera XT DNA Library Preparation Kit (Illumina) and the Nextera XT v2 Index Kit Set A (Illumina). Sequence analysis was then performed using Next-seq500 (Illumina) with a read length of 150 bp and paired end reads, yielding more than 10 million reads per sample.

[0090] (9) The nucleotide sequence (sequence data) decoded in (8) was mapped to the human genome sequence using TopHat2 (Johns Hopkins University) and Bowtie2 (Johns Hopkins University). The human genome sequence and human gene information were obtained using BUILD GRCh38, which is published by NCBI (National Center for Biological Information). The mapped nucleotide sequence was used to calculate the expression value of each gene in units of FPKM (Fragments Per Kilobase of exon per Million reads mapped) from the number of reads of each gene decoded using Cufflinks (Washington University).

[0091] (10) Of the 31 CTC samples, 10 samples were found to not express the epithelial marker EpCAM gene, and their expression was compared with that of leukocytes as epithelial marker-negative CTCs.

[0092] Table 1 shows genes whose average expression value (FPKM value) in epithelial marker-negative CTCs (10 samples) is 10.00 times or more the average expression value (FPKM value) in white blood cells (4 samples) and which encode transmembrane proteins. Among the above genes, the analysis results for the gene encoding RAMP2 (SEQ ID NO: 1) for each sample are shown in Figure 1. In Figure 1, WBC1 to WBC4 are the expression analysis results for white blood cells, and CTC1 to CTC10 are the expression analysis results for epithelial marker-negative CTCs.

[0093] The average expression value (FPKM value) of the RAMP2 gene (SEQ ID NO: 93) in epithelial marker-negative CTCs (10 samples) is 500 times higher than the average FPKM value of leukocytes (4 samples), indicating that the RAMP2 gene is specifically and highly expressed in epithelial marker-negative CTCs (Table 1). In addition, since the RAMP2 protein (SEQ ID NO: 1) is a transmembrane protein, it is suggested that epithelial marker-negative CTCs contained in the sample can be recovered.

[0094] Tables 2 to 4 show genes whose average expression value (FPKM value) in epithelial marker-negative CTCs (10 samples) was 10.00 times or more higher than the average expression value (FPKM value) in leukocytes (2 samples) and which encode proteins other than transmembrane proteins.

Claims

1. 1. A method for detecting a target cell in a sample, comprising: detecting a tumor marker in the sample, the detection signal of the tumor marker is 10.00 times or more higher than the detection signal of the marker in the negative control cells; the target cell is a tumor cell negative for at least one epithelial marker; The method according to claim 1, wherein the tumor marker is one or more polypeptides selected from the group consisting of the following (1) to (3): (1) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1; (2) A polypeptide comprising an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:1, which contains a deletion, substitution, insertion, and / or addition of 1 to 17 amino acid residues; (3) A polypeptide comprising an amino acid sequence having 90% or more homology to the entire amino acid sequence set forth in SEQ ID NO:

1.

2. The method of claim 1 , wherein the tumor marker is detected using an antibody or an aptamer that specifically recognizes the tumor marker.

3. The method of claim 1 , wherein the tumor marker is detected by detecting a transcription product of a gene encoding the tumor marker.

4. The method of any one of claims 1 to 3, wherein the sample contains contaminating cells.

5. The method of claim 4, wherein the contaminating cells are white blood cells.

6. The method according to any one of claims 1 to 5, wherein the sample is a sample obtained from a subject.

7. The method of claim 6 , wherein the subject is a cancer subject.

8. The method of claim 6 or 7, wherein the subject is a human.

9. The method according to any one of claims 1 to 8, wherein the sample is a blood-derived sample.

10. The method according to any one of claims 1 to 9, wherein the epithelial marker is cytokeratin and / or EpCAM (Epithelial cell adhesion molecule).

11. the sample is obtained from a subject, the subject is a cancer subject, The detection determines the number of the target cells in the sample. The method according to any one of claims 1 to 10.

12. 1. A method for recovering target cells in a sample, comprising: Detecting the target cells in the sample by the method according to any one of claims 1 to 11, and Recovering the detected target cells. A method comprising:

13. A method for acquiring data for predicting a prognosis of a subject, comprising: Determining the number of target cells in the sample by the method of claim 11; and Obtaining data correlating said number with a prognosis for said subject. A method comprising:

Citation Information

Patent Citations

  • A method to predict progression-free and overall survival at each follow-up point during therapy of patients with metastatic breast cancer using circulating tumor cells

    JP2008533487A

  • PODXL protein in colorectal cancer

    JP2013508736A

  • Methods for determining the characteristics of circulating tumor cells and their application to diagnosis

    JP2014533828A

  • Specific detection tools for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells

    JP2016512197A

  • Method for predicting prognosis of cancer patient by using rare cells

    JP2017129584A